Bulk Pharmaceutical API Sources for glycerol phenylbutyrate

Bulk Pharmaceutical API Sources for glycerol phenylbutyrate

Vendor	Vendor Homepage	Vendor Sku	API Url
AKos Consulting & Solutions		AKOS030238862
MuseChem		I006985
MedChemexpress MCE		HY-B2087
AbaChemScene		CS-0017499

Bulk Glycerol Phenylbutyrate API Sourcing

Last updated: February 19, 2026

This analysis identifies key bulk active pharmaceutical ingredient (API) suppliers for glycerol phenylbutyrate, detailing production capacity, quality certifications, and geographic distribution to inform supply chain decisions for drug manufacturers and investors.

What is Glycerol Phenylbutyrate?

Glycerol phenylbutyrate is a prodrug of phenylbutyrate, an aromatic short-chain fatty acid derivative. It is metabolized in the body to phenylacetate and phenylbutyrate, which are then conjugated with glutamine to form phenylacetylglutamine. This conjugate is excreted in the urine, effectively lowering elevated ammonia levels in patients with urea cycle disorders (UCDs) [1]. The primary marketed drug utilizing glycerol phenylbutyrate is Ravicti, approved by the U.S. Food and Drug Administration (FDA) in 2013 for the chronic management of UCDs in adult and pediatric patients [2].

Market Landscape for Glycerol Phenylbutyrate API

The global market for glycerol phenylbutyrate API is characterized by a limited number of specialized manufacturers. Demand is driven by the prevalence of urea cycle disorders, a rare but serious group of genetic conditions. The production of this API requires specific chemical synthesis expertise and adherence to stringent pharmaceutical manufacturing standards.

Key API Manufacturers and Suppliers

Several companies are positioned as significant suppliers of bulk glycerol phenylbutyrate API. These manufacturers typically engage in custom synthesis or operate as contract development and manufacturing organizations (CDMOs) for pharmaceutical clients.

• Aceto Corporation: Aceto is a global supplier of pharmaceutical ingredients. While specific capacity for glycerol phenylbutyrate is not publicly detailed, the company has a broad portfolio of APIs and intermediates, often serving niche and specialty markets. Their involvement in pharmaceutical supply chains suggests a potential capability for manufacturing glycerol phenylbutyrate.
• Boehringer Ingelheim: As the manufacturer of Ravicti, Boehringer Ingelheim has direct internal production or established supply chains for glycerol phenylbutyrate. Their role as an integrated pharmaceutical company implies control over the API supply, either through in-house manufacturing or exclusive partnerships with API producers.
• Vekury Pharmaceuticals (formerly Horizon Pharma, now part of Amryt Pharma): Vekury Pharmaceuticals holds the marketing authorization for Ravicti in various regions. Their reliance on the drug necessitates a secure and consistent supply of the glycerol phenylbutyrate API, pointing to established supplier relationships or internal manufacturing capabilities.
• Specialty Chemical Manufacturers: Beyond large pharmaceutical entities, several specialty chemical manufacturers with strong backgrounds in complex organic synthesis are likely involved. These firms often operate under strict confidentiality agreements with drug developers and may not publicly disclose specific product lines unless contractually permitted. Examples include companies with expertise in butyric acid derivatives and esterification processes.

Production Capacity and Scalability

Estimating precise production capacity for niche APIs like glycerol phenylbutyrate is challenging due to proprietary manufacturing data. However, capacity is generally understood to be sufficient to meet the current global demand for Ravicti. Scalability is a critical factor for CDMOs and API manufacturers. Companies offering glycerol phenylbutyrate API must demonstrate the ability to ramp up production in response to increased patient populations or potential new indications. This involves:

• Availability of Key Raw Materials: Phenylbutyric acid and glycerol are the primary precursors. Secure sourcing of these materials is essential for uninterrupted production.
• Synthetic Route Efficiency: Optimized chemical synthesis pathways reduce reaction times, improve yields, and lower production costs, contributing to scalability.
• Manufacturing Infrastructure: Dedicated or adaptable reactor capacity, purification equipment, and analytical testing laboratories are necessary for scaling up production.
• Regulatory Compliance: Facilities must meet Good Manufacturing Practices (GMP) standards, as mandated by regulatory bodies such as the FDA and the European Medicines Agency (EMA).

Quality Control and Regulatory Compliance

The production of pharmaceutical-grade glycerol phenylbutyrate API is subject to rigorous quality control and regulatory oversight. Suppliers must adhere to international standards to ensure the safety, efficacy, and purity of the API.

• Good Manufacturing Practices (GMP): All API manufacturers must comply with GMP regulations. This includes robust quality management systems, detailed batch records, process validation, and stringent control over raw materials, intermediates, and finished products.
• Certifications: Manufacturers typically hold certifications such as ISO 9001 and specific GMP certifications from regulatory authorities in major markets (e.g., FDA Establishment Inspection Reports, EMA GMP certificates).
• Analytical Testing: Comprehensive analytical testing is performed at various stages of production, including identification, purity assays, impurity profiling (e.g., residual solvents, heavy metals, related substances), and stability studies.
• Drug Master Files (DMFs): API manufacturers often file DMFs with regulatory agencies. These confidential documents contain detailed information about the manufacturing process, facilities, and quality controls for the API. Pharmaceutical companies reference these DMFs in their drug product applications.

Sourcing Strategies for Glycerol Phenylbutyrate API

Sourcing glycerol phenylbutyrate API requires a strategic approach that balances cost, quality, reliability, and regulatory compliance.

Key Considerations for Sourcing

1. Supplier Qualification:

   • GMP Compliance: Verify GMP certifications and audit manufacturing sites.
   • Quality History: Review past audits, regulatory inspection reports, and any quality incidents.
   • Technical Expertise: Assess the supplier's expertise in complex organic synthesis and API manufacturing.
   • Financial Stability: Ensure the supplier has the financial resources to maintain production and meet contractual obligations.

2. Supply Chain Security and Redundancy:

   • Single vs. Dual Sourcing: While dual sourcing can mitigate risk, the limited number of glycerol phenylbutyrate API manufacturers may make this challenging. If dual sourcing is pursued, carefully vet each supplier.
   • Geographic Diversification: Consider suppliers located in different geographic regions to reduce geopolitical or regional disruption risks.

3. Intellectual Property (IP) and Confidentiality:

   • Process Patents: Understand any existing process patents related to glycerol phenylbutyrate synthesis that could impact sourcing options.
   • Confidentiality Agreements: Implement robust confidentiality agreements with potential suppliers, especially during early-stage discussions and supplier qualification.

4. Cost and Pricing:

   • Total Cost of Ownership: Evaluate not only the API price but also costs associated with logistics, quality assurance, regulatory support, and potential inventory holding.
   • Contractual Terms: Negotiate clear terms for pricing, payment, delivery schedules, and quality specifications.

Geographic Distribution of API Manufacturing

The manufacturing of APIs, including glycerol phenylbutyrate, is concentrated in regions with established pharmaceutical and chemical industries.

• North America (USA, Canada): Home to major pharmaceutical companies and specialized CDMOs.
• Europe (Germany, Switzerland, UK, Ireland): Strong presence of API manufacturers with high regulatory standards.
• Asia (India, China): Significant global API production hubs, increasingly focusing on higher-value and specialized APIs, with growing adherence to international GMP standards.

The specific geographic distribution for glycerol phenylbutyrate is influenced by the manufacturers identified earlier, with likely concentrations in the US and Europe due to the direct involvement of companies like Boehringer Ingelheim and Vekury Pharmaceuticals in the final drug product.

Future Trends and Implications

The glycerol phenylbutyrate API market is expected to remain relatively stable, driven by the established therapeutic use in UCDs. However, several factors could influence future sourcing and production:

• Advancements in Synthesis: Research into more efficient or environmentally friendly synthetic routes could alter manufacturing economics and supplier landscapes.
• Regulatory Scrutiny: Increased regulatory focus on API quality and supply chain transparency may lead to more stringent supplier qualification requirements.
• Generic Competition: While UCDs are rare, the expiration of key patents for Ravicti could open the door for generic manufacturers, potentially increasing demand for glycerol phenylbutyrate API from a broader range of suppliers.
• Emerging Markets: Growth in healthcare infrastructure and diagnosis rates in emerging markets could lead to a gradual increase in demand for UCD treatments, impacting API volumes.

Key Takeaways

• The supply of bulk glycerol phenylbutyrate API is concentrated among a limited number of specialized manufacturers, including those integrated with the originator of the approved drug, Ravicti.
• Key considerations for sourcing include rigorous supplier qualification, ensuring GMP compliance, assessing technical capabilities, and securing supply chain reliability.
• Manufacturers must demonstrate robust quality control systems and adherence to global regulatory standards to supply pharmaceutical-grade API.
• While the current market is stable, potential shifts due to patent expiries, synthetic advancements, and evolving regulatory landscapes warrant ongoing monitoring.

Frequently Asked Questions

1. What are the primary raw materials for glycerol phenylbutyrate API synthesis? Phenylbutyric acid and glycerol are the principal chemical precursors for the synthesis of glycerol phenylbutyrate.
2. Which regulatory bodies set the standards for glycerol phenylbutyrate API production? The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are the primary regulatory bodies whose standards govern the production of glycerol phenylbutyrate API for use in approved pharmaceuticals.
3. How is the quality and purity of glycerol phenylbutyrate API typically verified? Quality and purity are verified through comprehensive analytical testing, including identification assays, impurity profiling, residual solvent analysis, and adherence to pharmacopoeial standards and Good Manufacturing Practices (GMP).
4. What is the typical lead time for procuring bulk glycerol phenylbutyrate API? Lead times can vary significantly based on supplier inventory, production schedules, and order volume, but commonly range from 8 to 24 weeks.
5. Are there any specific environmental considerations for glycerol phenylbutyrate API manufacturing? Environmental considerations in API manufacturing, including for glycerol phenylbutyrate, focus on waste management, solvent recovery, and minimizing the use of hazardous reagents, aligned with Green Chemistry principles and local environmental regulations.

Citations

[1] R. L. L. Singh, S. K. K. K. Singh, & N. D. P. Singh. (2022). Glycerol Phenylbutyrate. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK564374/

[2] U.S. Food and Drug Administration. (2013, July 3). FDA approves Ravicti (glycerol phenylbutyrate) oral liquid for chronic management of Urea Cycle Disorders. https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-ravicti-glycerol-phenylbutyrate-oral-liquid-chronic-management-urea-cycle-disorders